July 07, 2023
A Delaware federal judge ruled Friday that a patent covering Entresto, a blockbuster heart failure drug made by Novartis, is invalid for lacking an adequate written description, handing a win to three Indian generics makers and leading Novartis to say it will appeal.
September 28, 2022
A Delaware federal judge has thrown out declaratory judgment counterclaims lodged against Novartis by two generic-drug makers in multidistrict patent litigation over Novartis' heart medication Entresto, determining that the court lacks subject matter jurisdiction.